Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced Parkinsonian monkeys

Brain

Volumn 125, Issue 10, 2002, Pages 2191-2201

  Grondin, Richard ^a   Zhang, Zhiming ^a   Yi, Ai ^a   Cass, Wayne A ^a   Maswood, Navin ^a   Andersen, Anders H ^a   Elsberry, Dennis D ^b   Klein, Michael C ^c   Gerhardt, Greg A ^a   Gash, Don M ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b MEDTRONIC INC   (United States)

^c AMGEN INC   (United States)

Author keywords

Dopamine neurones; GDNF; Non human primates; Parkinson's disease; Regeneration

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; FEMALE; GLOBUS PALLIDUS; MESENCEPHALON; MONKEY; NERVE REGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL;

EID: 0036787532     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf234     Document Type: Article

References (38)

1. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1986; 39: 7-16.
2. Bensadoun J-C, Deglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 2000; 164: 15-24.
3. Bjorklund A, Lindvall A. Parkinson disease gene therapy moves toward the clinic [letter]. Nat Med 2000; 6: 1207-08.
4. Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. [Review]. Brain Res 2000; 886: 82-98.
5. Bowenkamp KE, David D, Lapchak PL, Henry MA, Grandholm AC, Hoffer BJ, et al. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat: a possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 1996; 111: 1-7.
6. Cass WA. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 1996; 16: 8132-9.
7. Choi-Lundberg DL, Lin Q, Chang Y-N, Chiang YL, Hay CM, Mohajeri H, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997; 275: 838-41.
8. Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged parkinsonian rat. Gene Ther 1999; 6: 1936-51.
9. Costa S, Iravani M, Pearce RK, Jenner P. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets. Eur J Pharmacol 2001; 412: 45-50.
10. Emborg-Knott ME, Domino EF. MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Exp Neurol 1998; 152: 214-20.
11. Fallon J, Reid S, Kinyamu R, Opole I, Ople R, Baratta J, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA 2000; 97: 14686-91.
12. Gash DM, Zhang Z, Cass WA, Ovadia L, Simmerman L, Martin D, et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 1995; 363: 345-58.
13. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-5.
14. Gash DM, Zhang Z, Gerhardt G. Neuroprotective and neurorestorative properties of GDNF. [Review]. Ann Neurol 1998; 44 (3 Suppl 1): S121-5.
15. Gould E, Gross CG. Neurogenesis in adult mammals: some progress and problems. [Review]. J Neurosci 2002; 22: 619-23.
16. Grondin R, Zhang Z, Elsberry DD, Gerhardt GA, Gash DM. Chronic intracerebral delivery of trophic factors via a programmable pump as a treatment for parkinsonism. In: Mouradian MM, editor. Parkinson's disease: methods and protocols. Totowa (NJ): Humana Press; 2001. p. 257-67.
17. Herkenham M, Little MD, Bankiewicz K, Tang SC, Markey SP, Johannessen JN. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991; 40: 133-58.
18. Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey. J Neurosci Methods 2000; 96: 71-6.
19. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1987; 45: 1-18.
20. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20: 4686-700.
21. Kirik D, Georgievska B, Rosenblad C, Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 2001; 13: 1589-99.
22. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl J Med 1988; 318: 876-80.
23. Kordower JH, Palfi S, Chen E-Y, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46: 419-24.
24. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73.
25. Lang AE, Lozano AM. Parkinson's disease. First of two parts. [Review]. New Engl J Med 1998a; 339: 1044-53.
26. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. [Review]. New Engl J Med 1998b; 339: 1130-43.
27. 125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Res 1998; 789: 9-22.
28. Lindner MD, Winn SR, Baetge EE, Hammang JP, Gentile FT, Doherty E, et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 1995; 132: 62-76.
29. Miyoshi Y, Zhang Z, Ovadia A, Lapchak PA, Collins F, Hilt D, et al. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Ann Neurol 1997; 42: 208-14.
30. Olson L. Combating Parkinson's disease-step three. Science 2000; 290: 721-4.
31. Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 1995; 16: 931-7.
32. Rosenblad C, Martinez-Serrano A, Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998; 82: 129-37.
33. Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. [Review]. Trends Neurosci 2000; 23 (10 Suppl): S28-33.
34. Smith RD, Zhang Z, Kurlan R, McDermott M, Gash DM. Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 1993; 52: 7-16.
35. Tomac A, Lindqvist E, Lin L-F, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995a; 373: 335-9.
36. Tomac A, Widenfalk J, Lin L-F, Kohno T, Ebendal T, Hoffer BJ, et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 1995b; 92: 8274-8.
37. Zhang Z, Miyoshi Y, Lapchak PA, Collins F, Hilt D, Lebel C, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997; 282: 1396-401.
38. Zhao M, Momma S, Delfani K, Johansson CB, Frisen J, Janson AM. Neurogenesis in the adult mammalian substantia nigra [abstract]. Soc Neurosci Abstr 2001; 27.